New pill shows promise for shedding pounds in overweight adults
NCT ID NCT07002905
First seen Jan 04, 2026 · Last updated May 01, 2026 · Updated 20 times
Summary
This study tested a new tablet called ASC30 to help people who are overweight or obese and have related health problems lose weight. About 125 adults took either the study drug or a placebo for 13 weeks. Researchers measured weight loss, waist size, and safety to see if the drug works and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC WEIGHT MANAGEMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ascletis Clinical Site
Rogers, Arkansas, 72758, United States
-
Ascletis Clinical Site
Fort Myers, Florida, 33912, United States
-
Ascletis Clinical Site
Miami, Florida, 33172, United States
-
Ascletis Clinical Site
Columbus, Ohio, 43212, United States
-
Ascletis Clinical Site
Bellaire, Texas, 77401, United States
-
Ascletis Clinical Site
San Antonio, Texas, 78240, United States
Conditions
Explore the condition pages connected to this study.